Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III trial of Lanifibranor

Trial Profile

A Phase III trial of Lanifibranor

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Non-alcoholic steatohepatitis; Systemic scleroderma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2018 New trial record
    • 13 Aug 2018 According to an Inventiva Pharma media release, the company has finalized the regulatory toxicological package necessary to enter into Phase III trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top